These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 29890520

  • 1. Overcoming Heparin-Associated RT-qPCR Inhibition and Normalization Issues for microRNA Quantification in Patients with Acute Myocardial Infarction.
    Coelho-Lima J, Mohammed A, Cormack S, Jones S, Das R, Egred M, Panahi P, Ali S, Spyridopoulos I.
    Thromb Haemost; 2018 Jul; 118(7):1257-1269. PubMed ID: 29890520
    [Abstract] [Full Text] [Related]

  • 2. miR-941 as a promising biomarker for acute coronary syndrome.
    Bai R, Yang Q, Xi R, Li L, Shi D, Chen K.
    BMC Cardiovasc Disord; 2017 Aug 22; 17(1):227. PubMed ID: 28830367
    [Abstract] [Full Text] [Related]

  • 3. Practical Procedures for Improving Detection of Circulating miRNAs in Cardiovascular Diseases.
    Chen CC, Peng CC, Fan PC, Chu PH, Chang YS, Chang CH.
    J Cardiovasc Transl Res; 2020 Dec 22; 13(6):977-987. PubMed ID: 32440912
    [Abstract] [Full Text] [Related]

  • 4. Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Via Radial Access Anticoagulated With Bivalirudin Versus Heparin: A Report From the National Cardiovascular Data Registry.
    Jovin IS, Shah RM, Patel DB, Rao SV, Baklanov DV, Moussa I, Kennedy KF, Secemsky EA, Yeh RW, Kontos MC, Vetrovec GW.
    JACC Cardiovasc Interv; 2017 Jun 12; 10(11):1102-1111. PubMed ID: 28527778
    [Abstract] [Full Text] [Related]

  • 5. Value of Serum miR-23a, miR-30d, and miR-146a Biomarkers in ST-Elevation Myocardial Infarction.
    Bukauskas T, Mickus R, Cereskevicius D, Macas A.
    Med Sci Monit; 2019 May 27; 25():3925-3932. PubMed ID: 31130720
    [Abstract] [Full Text] [Related]

  • 6. Improving Accuracy of Urinary miRNA Quantification in Heparinized Patients Using Heparinase I Digestion.
    Roest HP, Verhoeven CJ, de Haan JE, de Jonge J, IJzermans JN, van der Laan LJ.
    J Mol Diagn; 2016 Nov 27; 18(6):825-833. PubMed ID: 27598820
    [Abstract] [Full Text] [Related]

  • 7. Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarction-a registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-SWEDEHEART trial).
    Erlinge D, Koul S, Eriksson P, Scherstén F, Omerovic E, Linder R, Östlund OP, Wallentin L, Fröbert O, James S.
    Am Heart J; 2016 May 27; 175():36-46. PubMed ID: 27179722
    [Abstract] [Full Text] [Related]

  • 8. Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States.
    Secemsky EA, Kirtane A, Bangalore S, Jovin IS, Shah RM, Ferro EG, Wimmer NJ, Roe M, Dai D, Mauri L, Yeh RW.
    JACC Cardiovasc Interv; 2016 Dec 12; 9(23):2376-2386. PubMed ID: 27838271
    [Abstract] [Full Text] [Related]

  • 9. Bivalirudin Versus Heparin Monotherapy in Elderly Patients With Myocardial Infarction: A Prespecified Subgroup Analysis of the VALIDATE-SWEDEHEART Trial.
    Wester A, Attar R, Mohammad MA, Isma N, James S, Omerovic E, Erlinge D, Koul S.
    Circ Cardiovasc Interv; 2020 Apr 12; 13(4):e008671. PubMed ID: 32216471
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of prehospital administration of unfractionated heparin, enoxaparin or bivalirudin in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Insights from the ORBI registry.
    Auffret V, Leurent G, Boulmier D, Bedossa M, Zabalawi A, Hacot JP, Coudert I, Filippi E, Castellant P, Rialan A, Rouault G, Druelles P, Boulanger B, Treuil J, Avez B, Le Guellec M, Gilard M, Le Breton H.
    Arch Cardiovasc Dis; 2016 Dec 12; 109(12):696-707. PubMed ID: 27818120
    [Abstract] [Full Text] [Related]

  • 11. Heparinase treatment of heparin-contaminated plasma from coronary artery bypass grafting patients enables reliable quantification of microRNAs.
    Kondratov K, Kurapeev D, Popov M, Sidorova M, Minasian S, Galagudza M, Kostareva A, Fedorov A.
    Biomol Detect Quantif; 2016 Jun 12; 8():9-14. PubMed ID: 27335806
    [Abstract] [Full Text] [Related]

  • 12. Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: A subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial.
    Wang H, Li Y, Cong H, Ding S, Liu B, Li L, Chen Y, Jia S, Jing Q, Zhao X, Liu H, Liang Z, Li J, Bao D, Han Y.
    Catheter Cardiovasc Interv; 2017 Jun 01; 89(7):1157-1165. PubMed ID: 27677411
    [Abstract] [Full Text] [Related]

  • 13. Myocardial reperfusion for acute myocardial infarction under an optimized antithrombotic medication: What can you expect in daily practice?
    Pinelli S, Agrinier N, Bouchahda N, Metzdorf PA, Camenzind E, Popovic B.
    Cardiovasc Revasc Med; 2018 Jun 01; 19(7 Pt B):820-825. PubMed ID: 29555534
    [Abstract] [Full Text] [Related]

  • 14. Effect of postprocedural full-dose infusion of bivalirudin on acute stent thrombosis in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Outcomes in a large real-world population.
    Wang H, Liang Z, Li Y, Li B, Liu J, Hong X, Lu X, Wu J, Zhao W, Liu Q, An J, Li L, Pu F, Ming Q, Han Y.
    Cardiovasc Ther; 2017 Jun 01; 35(3):. PubMed ID: 28083915
    [Abstract] [Full Text] [Related]

  • 15. ST-segment resolution with bivalirudin versus heparin and routine glycoprotein IIb/IIIa inhibitors started in the ambulance in ST-segment elevation myocardial infarction patients transported for primary percutaneous coronary intervention: The EUROMAX ST-segment resolution substudy.
    Van't Hof A, Giannini F, Ten Berg J, Tolsma R, Clemmensen P, Bernstein D, Coste P, Goldstein P, Zeymer U, Hamm C, Deliargyris E, Steg PG.
    Eur Heart J Acute Cardiovasc Care; 2017 Aug 01; 6(5):404-411. PubMed ID: 26250825
    [Abstract] [Full Text] [Related]

  • 16. One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical Trial.
    Fabris E, Kilic S, Van't Hof AWJ, Ten Berg J, Ayesta A, Zeymer U, Hamon M, Soulat L, Bernstein D, Anthopoulos P, Deliargyris EN, Steg PG.
    JAMA Cardiol; 2017 Jul 01; 2(7):791-796. PubMed ID: 28273285
    [Abstract] [Full Text] [Related]

  • 17. Heparin Versus Bivalirudin Monotherapy in the Setting of Primary Percutaneous Coronary Intervention for Patients With ST-Segment Elevation Myocardial Infarction.
    Faulkenberg KD, Beavers JC, Finks SW.
    Ann Pharmacother; 2016 Feb 01; 50(2):141-51. PubMed ID: 26681442
    [Abstract] [Full Text] [Related]

  • 18. Circulating microRNAs in patients with ST-elevation myocardial infarction.
    Eryılmaz U, Akgüllü Ç, Beşer N, Yıldız Ö, Kurt Ömürlü İ, Bozdoğan B.
    Anatol J Cardiol; 2016 Jun 01; 16(6):392-6. PubMed ID: 27282672
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Evaluation of RNA isolation methods for microRNA quantification in a range of clinical biofluids.
    Roest HP, IJzermans JNM, van der Laan LJW.
    BMC Biotechnol; 2021 Aug 06; 21(1):48. PubMed ID: 34362351
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.